Medical Marijuana Inc.'s HempMedsPX Co-Sponsors Americans for Safe Access Unity Conference in Washington DC
Date : 04/03/2014 @ 9:00AM
Source : GlobeNewswire Inc.
Stock : Medical Marijuana, Inc. (PC) (MJNA)
Quote : 0.292 0.0 (0.00%) @ 8:40AM
Medical Marijuana Inc.'s HempMedsPX Co-Sponsors Americans for Safe Access Unity Conference in Washington DC
Print
Alert
Medical Marijuana, Inc. (PC) (USOTC:MJNA)
Intraday Stock Chart
Today : Thursday 3 April 2014
Click Here for more Medical Marijuana, Inc. (PC) Charts.
Medical Marijuana Inc. (OTC Pink:MJNA) is pleased to announce that its subsidiary company, HempMedsPX™, will participate in the Americans for Safe Access (ASA) 2nd Annual National Medical Cannabis Unity Conference, Navigating Medical Cannabis in the Mainstream, in Washington D.C. The conference takes place at the Mayflower Renaissance Hotel April 5 – 7, 2014. ASA's goal is to express "strength in unity" to the current administration with regard to changing policies that prevent safe access to cannabis. Cannabidiol (CBD) is a hot topic that HempMedsPX™ will discuss with medical doctors, legal experts, and policymakers during ASA's Unity Conference.
HempMedsPX logo
"We appreciate all that ASA is doing to educate the public about safe access to medical cannabis," states Charles Vest, VP of Communications for HempMedsPX™. "We are participating in ASA's Unity Conference to convey our belief that there needs to be 'access for all.'"
In 2013, ASA donors sponsored 125 patients from thirty-four states to attend the national conference. These patients participated in the largest medical cannabis lobby day in US history visiting more than 300 Congressional offices that day.
"We are so fortunate to have HempMeds joining us as Partnering Sponsor at this year's Unity Conference," states Steph Sherer, Executive Director of Americans for Safe Access. "Their generous contribution helped ASA grant scholarships to 152 advocates from 37 states who will be bringing their messages to the halls of Congress."
ASA's Unity Conference agenda includes presentations on the history of botanical medicines in the US, the future of regulation and product safety, and a panel discussion: "CBD the Myths and the Facts." The conference includes a trip to Capitol Hill. There, ASA will host a press conference, brief Hill staff on medical marijuana, and lobby Capitol Hill with hundreds of patient advocates.
One of Medical Marijuana, Inc.'s investment holdings is KannaLife Sciences, Inc., a socially responsible, bio-pharmaceutical and phyto-medical company specializing in the research and development of pharmacological products derived from plants. Current target drug candidates are to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). KannaLife Sciences, Inc. is involved in the research and development of novel therapeutic agents designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants and currently holds an exclusive license agreement with the National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the commercialization of U.S. Patent #6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"). The Company's Chairman and Chief Executive Officer will take part in ASA's panel discussion: "CBD the Myths and the Facts."
"Acceptance of cannabis as a natural product is spreading nationwide. Until nationwide cannabis legalization is achieved, we simply want to give people without access another choice with our CBD-rich hemp oil products. Between more and more states legalizing medical marijuana, and the reintroduction of hemp agriculture thanks to the 2014 Farm Bill, this is an exciting time to be part of the effort to legalize cannabis for all," Vest concludes
